Compare Manchester United PLC (MANU) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Travere Therapeutics Inc. Common Stock — how do they compare? Manchester United PLC trades at $20.68 (market cap $3.64B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Manchester United PLC pays a 1.26% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MANU | TVTX | |
|---|---|---|
Market Cap | $3.64B | $4.88B |
Volume | 324,608 | 1,668,577 |
Sector | Media | Health |
52-Week High | $24.19 | $67.52 |
52-Week Low | $15.20 | $26.79 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $4.46B | $5.01B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.59, down 1.15% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported fiscal 2026 revenue of $678 million with improved EBITDA of $216.4 million despite net losses, while analyst sentiment remains divided with 40% buy ratings. Recent news highlights the stock trading at a significant discount to Forbes' $7.2 billion franchise valuation estimate.
Investment outlook balances franchise value upside against persistent profitability challenges. Key opportunities include Champions League return and cost controls, while risks center on sustained losses, high debt, and competitive Premier League dynamics. The stock offers speculative appeal for franchise value believers but requires profitability improvement for sustained gains.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
